drugset
drugset / Trial / NCT02778386

Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

NCT02778386 ↗

Phase 1 Unknown 28 enrolled N&N Pharmaceuticals Inc.
Non-randomizedSingle-groupOpen-labelHealth-services research

Summary

This Phase I evaluation of N-MCT in normal volunteers requires sequentially increased doses. At each dose level, the safety and pharmacokinetic will be measured. This Phase I trial will have the dose range of N-MCT from 200mg - 1200mg per patient.

Timeline

Start
2016-04
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject (NORTH)-METHANOCARBATHYMIDINE Small molecule 200 mg Oral
Subject (NORTH)-METHANOCARBATHYMIDINE Small molecule 400 mg Oral
Subject (NORTH)-METHANOCARBATHYMIDINE Small molecule 800 mg Oral
Subject (NORTH)-METHANOCARBATHYMIDINE Small molecule 1200 mg Oral

Indications

poisoning